CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The Pink Sheet takes an exclusive look at the complete response letter, which shows the information on application deficiencies that could become widely available if FDA leaders succeed in releasing CRLs in real time.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.
